HLB CI
“[Financial News] Interest in the expandability and value of new drugs is increasing as the combination therapy of HLB’s ‘riboceranib (Chinese name apatinib)’ and Hangsung Pharmaceuticals’ ‘camrellizumab’ has significantly increased the success rate of surgery as a pre-treatment for stage 3 non-small cell lung cancer (NSCLC) patients.”
“On the 16th, according to HLB, the research results will be orally presented at the ‘World Conference on Lung Cancer Annual Conference (WCLC 2024)’ to be held in San Diego, USA from September 7th to 10th.”
“According to the abstract disclosed earlier, in a phase 2 clinical trial conducted on 29 patients, complete resection was achieved in 19 patients. The major pathological response rate (MPR) was 36.8%, and the pathological complete response rate (pCR) was also 36.8%.”
“In addition, the objective response rate (ORR) was 86.2%, and downstaging was observed in 20.7% of patients where the size of the tumor decreased.”
“As of now, the overall survival data for all patients in this clinical trial is not yet available.”
“The research team conducting the clinical trial stated, ‘The results of this study demonstrate the high potential of riboceranib combination therapy as a pre-surgical treatment, and it is expected to provide new hope in the treatment of NSCLC.'”
“The combination therapy of riboceranib and camrellizumab has been proven to be an effective treatment in adjuvant therapy before surgery for various solid tumors such as stomach cancer, liver cancer, esophageal cancer, and colorectal cancer. The clear efficacy in lung cancer clinical trials this time is seen as a positive sign for HLB’s expansion. ”
“HLB, which is preparing for the restart of liver cancer main-stage studies, is considering expanding clinical trials for adjuvant therapy before and after liver cancer surgery. Partner organization Hangsung Pharmaceuticals is actively conducting phase 3 clinical trials for liver cancer adjuvant therapy in China, making it likely to expand to global phase 3 trials. With proven high efficacy and safety not only in liver cancer but also in lung cancer, expectations are high for global expansion of clinical trials for various solid tumors.”